| abstract |
Recombinant antibody comprising: (i) a binding domain that is capable of binding to a target molecule; and (ii) an effector domain; wherein the recombinant antibody is capable of binding to the target molecule without activating a significant complement-dependent lysis, or cell-mediated destruction of the target, and in which the effector domain is - capable of specifically binding to FcγRIIb, and - a domain chimeric that is derived from two or more human immunoglobulin heavy chain CH2 domains, whose human immunoglobulins are selected from IgG1, IgG2 and IgG4, and wherein the chimeric domain is a human immunoglobulin heavy chain CH2 domain having the following blocks of amino acids in the indicated positions: 233P, 234V, 235A and 236G 327G and, 330S and 331 S according to the EU numbering system, and is at least 98% identical to a CH2 sequence (residues 231-340) of the IgG1, IgG2 or human IgG4 having said modified amino acids. |